https://www.selleckchem.com/pr....oducts/lonidamine.ht
This study aimed to evaluate hearing improvement at different frequencies and the safety of intratympanic (IT) and intravenous (IV) administration of dexamethasone for sudden sensorineural hearing loss (SSNHL). SSNHL patients were randomly divided into two groups within 72hours after onset and received 24days of dexamethasone therapy. Group A received IT dexamethasone once every other day for 24days. Group B received IV dexamethasone for 12days, followed by IT dexamethasone once every other day for the following 12days. Hearing recov